Restricting the dataset to patients with advanced stages of CKD (i.e. stages 3–5, n = 130 patients, n = 41 outcomes), did not markedly alter the association of hepcidin to mortality and also not the interaction of EPO and hepcidin, but age, gender and history of CVD lost significance (detailed data not shown). The gene discussed is EPO; the disease is chronic kidney disease.